Clinical Trial Update: Tocilizumab Dose-tapering and Interruption in Patients With Giant Cell Arteritis Achieving the Clinical Remission. [Phase 4]

View source ↗

Summary

Phase 4 trial update on dose-tapering and interruption of tocilizumab in Giant Cell Arteritis patients who have achieved clinical remission.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Giant Cell Arteritis

Drugs mentioned

• Tocilizumab (tocilizumab)

Snippet

Sponsor: Hospital of Prato | Conditions: Giant Cell Arteritis | Phase 4 | Status: UNKNOWN